NE-100: A novel sigma receptor antagonist

CNS Drug Reviews

Volumn 2, Issue 2, 1996, Pages 226-237

  Okuyama, Shigeru ^a   Nakazato, Atsuro ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

100; NE; Neuroleptics; Phencyclidine psychosis; Sigma receptor ligand

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; PHENCYCLIDINE;

ATAXIA; BINDING AFFINITY; DRUG RECEPTOR BINDING; HUMAN; HYPERACTIVITY; PSYCHOSIS; REVIEW; STEREOTYPY;

EID: 0030017401     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00299.x     Document Type: Review

References (41)

1. Boyce B, Rupniak NMJ, Steventon G, Cook G, Iversen SD. Psychomotor activity and cognitive disruption attributable to NMDA, but not sigma, interaction in primates. Brain Res 1991;42:115-121.
2. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. Trends in Neurosci 1990;13:272-276.
3. 1 binding sites in guinea pig brain. Eur J Pharmacol 1994;251:R1-R2.
4. Diana G, Scotti de Carolis A, Popoli P, Pezzola A, Sagratella S. Non-opioid antitussives potentiate some behavioural and EEG effects of N-methyl-D-aspartate channel blockers. Life Sci 1993;52:1547-1557.
5. 3H]glutamate binding. Soc Neurosci Abstr 1992;18:978.
6. Gao X-M, Shirakawa O, Du F, Tamminga CA. Delayed regional metabolic action of phencyclidine. Eur J Pharmacol 1993;241:7-15.
7. Gewirtz GR, Gorman JM, Volavka J, et al. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacol 1994;10:37-40.
8. Gilligan PJ, Tam SW. Sigma receptor ligands: Potential drugs for the treatment of CNS disorders? Drug News Perspectives 1994;7:13-18.
9. Grynne BH, Holmen AT, Maurset A. Evidence for distinct phencyclidine and SKF10047 receptors following detergent treatment of rat brain membranes. Pharmacol Toxicol 1992;70:25-30.
10. Holzman SG. Discriminative stimulus effects of the PCP/sigma-ligand (+)-N-allylnormetazocine in monkeys. Pharmacol Biochem Behav 1993;44:349-355.
11. Hudzik TJ, Slifer, BL. Interaction of sigma and PCP-like drugs on operant behaviors in the rat. Psychopharmacol 1992;108:115-122.
12. Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. J Clin Psychiatry 1987;9:12-35.
13. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.
14. 3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J Pharmacol Exp Ther 1986;238: 739-748.
15. Largent BL, Wikstrom H, Snowman AM, Synder SH. Novel antipsychotic drugs share high affinity for o- receptors. Eur J Pharmacol 1988;155:345-347.
16. Levinson DF. Pharmacologic treatment of schizophrenia. Clin Ther 1991;13:326-352.
17. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197:517-532.
18. Nakazato A, Sekiguchi Y, Ohta K, et al. Sigma-selective antagonists. 206th ACS National Meeting 1993: 181.
19. Ogawa S, Okuyama S, Araki H, Nakazato A, Otomo S. A rat model of phencyclidine psychosis. Life Sci 1994;55:1605-1610.
20. Ogawa S, Okuyama S, Araki H, Otomo S. Effect of NE-100, a novel σ receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur J Pharmacol 1994;263:9-15.
21. Ogawa S, Okuyama S, Araki H, Otomo S. The sigma-selective ligand NE-100 attenuates the effect of phencyclidine in a rat diving model. Gen Pharmacol 1995;26:177-182.
22. 3H]NE-100 in guinea pig brain. Life Sci 1995;57:PL333-337.
23. Okuyama S., Imagawa Y, Tomizawa K. Behavioral evidence for modulation by sigma ligands of (+)MK-801-induced hyperlocomotion in monoamine-depleted mice. Neuropharmacol 1996 (in press).
24. Okuyama S, Imagawa Y, Ogawa S, et al. NE-100, a novel sigma receptor ligand: In vivo test. Life Sci 1993;53:PL285-290.
25. Okuyama S, Imagawa Y, Sakagawa T, et al. NE-100, a novel sigma receptor ligand: Effect on phencyclidine-induced behaviors in rats, dogs and monkeys. Life Sci 1994;55:133-138.
26. Okuyama S, Ogawa S, Nakazato A, Tomizawa K. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci Lett 1995;189:60-62.
27. Reynolds GP. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 1992;13:116-121.
28. Sagratella A, Scotti de Carolis A, Pezzola A, Popoli P. Behavioural and electroencephalographic interactions between haloperidol and PCP/sigma ligands in the rat. Psychopharmacol 1991;105:485-491.
29. Schwarcz G, Halaris A, Dren A, Manberg P. Open-label evaluation of the novel antipsychotic compound BW 234U in chronic schizophrenics. Drug Dev Res 1985;5:387-393.
30. Sharp FR, Butman M. Wang S, et al. Haloperidol prevents induction of the hsp7O heat shock gene in neurons injured by phencyclidine (PCP), MK-801, and ketamine. J Neurosci Res 1992;33:605-616.
31. Snyder SH, Largent BL. Receptor mechanisms in antipsychotic drug action: Focus on sigma receptors. J Neuropsychiatry 1989;1:7-15.
32. Tamminga CA, Thaker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alteration with deficit syndrome. Arch Gen Psychiatry 1992;49:522-530.
33. Toru M, Kurumaji A, Ishimaru M. Excitatory amino acids: Implications for psychiatric disorders research. Life Sci 1994;55:1683-1699.
34. Tsung-Ping SU. Sigma receptors, putative links between neurons, endocrine, and immune systems. Eur J Biochem 1991;200:633-642.
35. Wadworth AN, Heel RC. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potentials in schizophrenia. Drugs 1990;40:867-879.
36. Wakatabe H, Nakano T, Tanaka T, et al. Phase I clinical study of NE-100, a new psychotropic drug for schizophrenia with selective sigma antagonist activity. 18th Annual Meeting of the Canadian College of Neuropsychopharmacology: A joint Meeting with the Japanese Society of Neuropsychopharmacology (Suppl.) 1995:21.
37. Walker JM, Dowen WD, Walker FO, Matsumoto RR, Costa BD, Rice KC. Sigma receptor: Biology and function. Pharmacol Rev 1990;42:335-402.
38. Weissman AD, Su TP, Hedreen JC, London ED. Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 1988;247:29-33.
39. Weissman AD, Casanova MF, Kleinman JE, London ED, De-Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites, in schizophrenia. Biol Psychiatry 1991;29:41-54.
40. Yamaguchi K, Nabeshima T, Kameyama T. Role of dopaminergic and serotonergic neuronal systems in the prefrontal cortex of rats in phencyclidine-induced behaviors. J Pharmacobio Dyn 1986;9:987-996.
41. 3H]TCP binding to intact primary cultured neuronal cells. Life Sci 1994;56:39-43.